UK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 inhibitor will succeed ... is an IL-6 inhibiting drug that was originally developed ...

Inhibiting the entire receptor complex prevents IL-6 ... inhibitor, may be beneficial for the treatment of RA in patients who do not respond to methotrexate or disease-modifying antirheumatic drugs.

The proteins associated with the target of CDK4/6 inhibitor were down-regulated among IR patients [NF-kB p105, CK8 (phosphor S431), and Cyclin D1], suggesting that the IR could be partially explained ...

Approved drugs are statins, PCSK9 Inhibitors ... The rationale for TRML’s TED program with an IL-6 inhibitor is that, as the company says, they have “identified a substantial body of published ...

Key drugs in other therapeutic areas include Hemlibra, a bispecific antibody created by Chugai that has changed the treatment landscape for hemophilia A, and Actemra, an IL-6 inhibitor for ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals ...

Few rigorous studies have examined biologic drugs as first-line treatment in ... Five patients started the IL-6 inhibitor tocilizumab (Actemra). In the group initiating conventional DMARDs ...

The discovery broadens the known spectrum of this rare disorder, emphasizing the critical role of collaboration with patient ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...